View in EDS

Patient-reported outcomes with belantamab mafodotin, pomalidomide, and dexamethasone versus bortezomib, pomalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-8): a phase 3, open-label, randomised controlled trial.

Saved in:
Bibliographic Details
Title: Patient-reported outcomes with belantamab mafodotin, pomalidomide, and dexamethasone versus bortezomib, pomalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-8): a phase 3, open-label, randomised controlled trial.
Authors: Dimopoulos MA; Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece; Department of Medicine, Korea University, Seoul, Republic of Korea. Electronic address: mdimop@med.uoa.gr., Beksac M; Department of Hematology, Ankara Liv Hospital, Istinye University, Ankara, Turkey., Pour L; Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, Brno, Czech Republic., Delimpasi S; General Hospital Evangelismos, Athens, Greece., Vorobyev V; Leningrad Regional Clinical Hospital, Saint Petersburg, Russian Federation., Quach H; University of Melbourne, St Vincent's Hospital, Melbourne, VIC, Australia., Spicka I; First Faculty of Medicine, Charles University and General Hospital, Prague, Czech Republic., Radocha J; 4th Department of Internal Medicine-Hematology, University Hospital Hradec Kralove, Charles University, Faculty of Medicine in Hradec Kralove, Hradec Kralove, Czech Republic., Robak P; Medical University of Łódź, Łódź, Poland., Kim K; Department of Medicine, Sungkyunkwan University, Samsung Medical Center, Seoul, Republic of Korea., Cavo M; Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy., Suzuki K; Division of Clinical Oncology and Hematology, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan., Wilkes J; GSK, Stevenage, UK., McNamara S; GSK, Stevenage, UK., Phillips-Jones A; GSK, Stevenage, UK., Morris K; GSK, Durham, NC, USA., Pompilus F; GSK, Philadelphia, PA, USA., Purser M; GSK, Collegeville, PA, USA., Sule N; GSK, Collegeville, PA, USA., Kremer B; GSK, Collegeville, PA, USA., Loubert A; Modus Outcomes, a THREAD Company, Lyon, France., Bunod L; Modus Outcomes, a THREAD Company, Lyon, France., M'Hari M; Modus Outcomes, a THREAD Company, Lyon, France., Zhou XL; GSK, Waltham, MA, USA., Fulci G; GSK, Waltham, MA, USA., Mateos MV; Hematology Department, University Hospital of Salamanca/IBSAL/Cancer Research Center-IBMCC, Salamanca, Spain., Trudel S; Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada.
Corporate Authors: DREAMM-8 investigators
Source: The Lancet. Haematology [Lancet Haematol] 2025 Nov; Vol. 12 (11), pp. e876-e886.
Publication Type: Journal Article; Randomized Controlled Trial; Clinical Trial, Phase III; Multicenter Study; Comparative Study
Journal Info: Publisher: Elsevier Ltd Country of Publication: England NLM ID: 101643584 Publication Model: Print Cited Medium: Internet ISSN: 2352-3026 (Electronic) Linking ISSN: 23523026 NLM ISO Abbreviation: Lancet Haematol Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 41193117
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Patient-reported outcomes with belantamab mafodotin, pomalidomide, and dexamethasone versus bortezomib, pomalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-8): a phase 3, open-label, randomised controlled trial.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Dimopoulos+MA%22">Dimopoulos MA</searchLink>; Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece; Department of Medicine, Korea University, Seoul, Republic of Korea. Electronic address: mdimop@med.uoa.gr.<br /><searchLink fieldCode="AU" term="%22Beksac+M%22">Beksac M</searchLink>; Department of Hematology, Ankara Liv Hospital, Istinye University, Ankara, Turkey.<br /><searchLink fieldCode="AU" term="%22Pour+L%22">Pour L</searchLink>; Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, Brno, Czech Republic.<br /><searchLink fieldCode="AU" term="%22Delimpasi+S%22">Delimpasi S</searchLink>; General Hospital Evangelismos, Athens, Greece.<br /><searchLink fieldCode="AU" term="%22Vorobyev+V%22">Vorobyev V</searchLink>; Leningrad Regional Clinical Hospital, Saint Petersburg, Russian Federation.<br /><searchLink fieldCode="AU" term="%22Quach+H%22">Quach H</searchLink>; University of Melbourne, St Vincent's Hospital, Melbourne, VIC, Australia.<br /><searchLink fieldCode="AU" term="%22Spicka+I%22">Spicka I</searchLink>; First Faculty of Medicine, Charles University and General Hospital, Prague, Czech Republic.<br /><searchLink fieldCode="AU" term="%22Radocha+J%22">Radocha J</searchLink>; 4th Department of Internal Medicine-Hematology, University Hospital Hradec Kralove, Charles University, Faculty of Medicine in Hradec Kralove, Hradec Kralove, Czech Republic.<br /><searchLink fieldCode="AU" term="%22Robak+P%22">Robak P</searchLink>; Medical University of Łódź, Łódź, Poland.<br /><searchLink fieldCode="AU" term="%22Kim+K%22">Kim K</searchLink>; Department of Medicine, Sungkyunkwan University, Samsung Medical Center, Seoul, Republic of Korea.<br /><searchLink fieldCode="AU" term="%22Cavo+M%22">Cavo M</searchLink>; Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy.<br /><searchLink fieldCode="AU" term="%22Suzuki+K%22">Suzuki K</searchLink>; Division of Clinical Oncology and Hematology, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan.<br /><searchLink fieldCode="AU" term="%22Wilkes+J%22">Wilkes J</searchLink>; GSK, Stevenage, UK.<br /><searchLink fieldCode="AU" term="%22McNamara+S%22">McNamara S</searchLink>; GSK, Stevenage, UK.<br /><searchLink fieldCode="AU" term="%22Phillips-Jones+A%22">Phillips-Jones A</searchLink>; GSK, Stevenage, UK.<br /><searchLink fieldCode="AU" term="%22Morris+K%22">Morris K</searchLink>; GSK, Durham, NC, USA.<br /><searchLink fieldCode="AU" term="%22Pompilus+F%22">Pompilus F</searchLink>; GSK, Philadelphia, PA, USA.<br /><searchLink fieldCode="AU" term="%22Purser+M%22">Purser M</searchLink>; GSK, Collegeville, PA, USA.<br /><searchLink fieldCode="AU" term="%22Sule+N%22">Sule N</searchLink>; GSK, Collegeville, PA, USA.<br /><searchLink fieldCode="AU" term="%22Kremer+B%22">Kremer B</searchLink>; GSK, Collegeville, PA, USA.<br /><searchLink fieldCode="AU" term="%22Loubert+A%22">Loubert A</searchLink>; Modus Outcomes, a THREAD Company, Lyon, France.<br /><searchLink fieldCode="AU" term="%22Bunod+L%22">Bunod L</searchLink>; Modus Outcomes, a THREAD Company, Lyon, France.<br /><searchLink fieldCode="AU" term="%22M'Hari+M%22">M'Hari M</searchLink>; Modus Outcomes, a THREAD Company, Lyon, France.<br /><searchLink fieldCode="AU" term="%22Zhou+XL%22">Zhou XL</searchLink>; GSK, Waltham, MA, USA.<br /><searchLink fieldCode="AU" term="%22Fulci+G%22">Fulci G</searchLink>; GSK, Waltham, MA, USA.<br /><searchLink fieldCode="AU" term="%22Mateos+MV%22">Mateos MV</searchLink>; Hematology Department, University Hospital of Salamanca/IBSAL/Cancer Research Center-IBMCC, Salamanca, Spain.<br /><searchLink fieldCode="AU" term="%22Trudel+S%22">Trudel S</searchLink>; Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada.
– Name: AuthorCorporate
  Label: Corporate Authors
  Group: Au
  Data: <searchLink fieldCode="CA" term="%22DREAMM-8+investigators%22">DREAMM-8 investigators</searchLink>
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101643584%22">The Lancet. Haematology</searchLink> [Lancet Haematol] 2025 Nov; Vol. 12 (11), pp. e876-e886.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Randomized Controlled Trial; Clinical Trial, Phase III; Multicenter Study; Comparative Study
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Elsevier+Ltd%22">Elsevier Ltd </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>101643584 <i>Publication Model: </i>Print <i>Cited Medium: </i>Internet <i>ISSN: </i>2352-3026 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2223523026%22">23523026 </searchLink><i>NLM ISO Abbreviation: </i>Lancet Haematol <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=41193117
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/S2352-3026(25)00256-X
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: e876
    Titles:
      – TitleFull: Patient-reported outcomes with belantamab mafodotin, pomalidomide, and dexamethasone versus bortezomib, pomalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-8): a phase 3, open-label, randomised controlled trial.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Dimopoulos MA
      – PersonEntity:
          Name:
            NameFull: Beksac M
      – PersonEntity:
          Name:
            NameFull: Pour L
      – PersonEntity:
          Name:
            NameFull: Delimpasi S
      – PersonEntity:
          Name:
            NameFull: Vorobyev V
      – PersonEntity:
          Name:
            NameFull: Quach H
      – PersonEntity:
          Name:
            NameFull: Spicka I
      – PersonEntity:
          Name:
            NameFull: Radocha J
      – PersonEntity:
          Name:
            NameFull: Robak P
      – PersonEntity:
          Name:
            NameFull: Kim K
      – PersonEntity:
          Name:
            NameFull: Cavo M
      – PersonEntity:
          Name:
            NameFull: Suzuki K
      – PersonEntity:
          Name:
            NameFull: Wilkes J
      – PersonEntity:
          Name:
            NameFull: McNamara S
      – PersonEntity:
          Name:
            NameFull: Phillips-Jones A
      – PersonEntity:
          Name:
            NameFull: Morris K
      – PersonEntity:
          Name:
            NameFull: Pompilus F
      – PersonEntity:
          Name:
            NameFull: Purser M
      – PersonEntity:
          Name:
            NameFull: Sule N
      – PersonEntity:
          Name:
            NameFull: Kremer B
      – PersonEntity:
          Name:
            NameFull: Loubert A
      – PersonEntity:
          Name:
            NameFull: Bunod L
      – PersonEntity:
          Name:
            NameFull: M'Hari M
      – PersonEntity:
          Name:
            NameFull: Zhou XL
      – PersonEntity:
          Name:
            NameFull: Fulci G
      – PersonEntity:
          Name:
            NameFull: Mateos MV
      – PersonEntity:
          Name:
            NameFull: Trudel S
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 11
              Text: 2025 Nov
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-electronic
              Value: 2352-3026
          Numbering:
            – Type: volume
              Value: 12
            – Type: issue
              Value: 11
          Titles:
            – TitleFull: The Lancet. Haematology
              Type: main
ResultId 1